Figure 2From: Pharmacogenomics of chemotherapeutic susceptibility and toxicityTranslation between cell-based models and clinical studies is bidirectional. The identification of SNPs associated with drug response from a GWAS in LCLs has to be confirmed in patient studies to determine clinical significance. Conversely, SNPs associated with drug response that are identified in a patient cohort and are confirmed in a validation cohort can be experimentally tested in the LCL model to determine biological significance.Back to article page